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1698 The Journal of Thoracic and CardObjective: Because of limited medical and surgical options for patients with end-
stage congestive heart failure, we expanded the criteria for surgical ventricular
remodeling to include patients with multiterritory myocardial infarction, a group
historically considered high-risk candidates. We present our series of patients with
multiterritory myocardial infarction who underwent surgical ventricular remodeling
and propose a new patient population who may benefit from this procedure.
Methods: Data were analyzed for 51 consecutive patients undergoing surgical
ventricular remodeling from January 2002 to June 2004, with 100% follow-up.
Three left ventricular vascular territories were defined: anteroapicoseptal (left an-
terior descending), lateral (circumflex), and inferior (right coronary artery). Infarc-
tion was assessed with magnetic resonance imaging and intraoperative findings.
Results: Multiterritory myocardial infarction was found in 64.7% of patients (33/51)
undergoing surgical ventricular remodeling. Mean age was 61.6 11.1 years (range
40-81 years). Sixty-one percent (20/33) demonstrated evidence of myocardial
infarction in all three territories. Five patients underwent concomitant mitral valve
repair or replacement. Operative mortality was 6.1% (2/33) and did not differ from
that of patients with single-territory infarction (11.1%, P  .61). Surgical ventric-
ular remodeling significantly improved left ventricular volumes and ejection frac-
tion in patients with multiterritory myocardial infarction. Three patients required
assist device implantation, and 2 patients required defibrillator placement. Sixty-
nine percent of patients in preoperative New York Heart Association functional
class III or IV (22/32) had improvement to class I or II at follow-up (P  .01). Cox
regression analysis discriminated a preoperative left ventricular end-systolic volume
index greater than 100 mL/m2 as a significant risk factor for mortality (odds ratio
12.1, 95% confidence interval 1.27-114.51, P  .03). Thirty-month survival of
patients with multiterritory myocardial infarction (73.5%  8.3%) did not differ
statistically from that of patients with single-territory infarction (n  18).
Conclusion: Surgical ventricular remodeling improves cardiac function and New
York Heart Association functional status in patients with multiterritory myocardial
infarction. Our initial results are promising and should prompt further studies to
confirm our results and potentially expand the surgical ventricular remodeling
inclusion criteria to include patients with multiterritory myocardial infarction.
The prevalence of congestive heart failure (CHF) in the United States isapproximately 5 million patients, and it is increasing yearly.1 Ischemiccardiomyopathy is the cause of CHF in 3 million of these patients.1 Approx-
imately 35% to 50% of patients with CHF will die within 2 years without treat-
ment.2,3 Although medical treatments are effective in the short term, cardiac
transplantation is widely accepted as the criterion standard therapy for the treatment
of CHF. Unfortunately, transplantation is limited by lack of donors, is expensive,
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most patients. Thus, alternatives are needed for patients
with advanced CHF.
Surgical ventricular remodeling (SVR) aims to amelio-
rate the progression of CHF by preventing further dilatation
of the left ventricle, reducing myocardial wall stress, and
restoring the shape and size of the chamber to improve left
ventricular function. Current indications for SVR include
single-territory myocardial infarction (STI); depressed ejec-
tion fraction (EF); left ventricular end-diastolic volume
index (LVEDVI) greater than 100 mL/m2; left ventricular
regional akinesia or dyskinesia; angina, CHF, or arrhyth-
mias; and inducible ischemia in symptom-free patients.4
Relative contraindications include right ventricular hypoki-
nesis, pulmonary hypertension, unreconstructable coronary
artery disease, and myocardial infarction (MI) in multiple
left ventricular territories (MTI).4,5
With these criteria, results of SVR for the treatment of
CHF have been excellent. Mickleborough and colleagues5
and Di Donato and associates6 have independently reported
excellent 5- and 10-year survivals, with acceptable opera-
tive mortality.5,6 The Reconstructive Endovascular Surgery
returning Torsion Original Radius Elliptical shape (RE-
STORE) multicenter study recently reported an operative
mortality of 5.3% and an actuarial 5-year survival of 69%
(22 patients at risk) in their cohort of 1198 patients with STI
leading to CHF.7
Most authors consider MTI to be a contraindication for
SVR because of the increased operative risks. However, no
Abbreviations and Acronyms
CHF  congestive heart failure
EF  ejection fraction
IABP  intra-aortic balloon pump
LVAD  left ventricular assist device
LVESVI  left ventricular end-systolic volume
index
LVEDVI  left ventricular end-diastolic volume
index
MI myocardial infarction
MR mitral regurgitation
MRI magnetic resonance imaging
MTI multiterritory myocardial infarction
NYHA  New York Heart Association
POD  postoperative day
RESTORE Reconstructive Endovascular Surgery
returning Torsion Original Radius
Elliptical shape
STI  single-territory myocardial infarction
SVR  surgical ventricular remodelingstudies have clearly shown these patients to be at higher
The Journal of Thoracicrisk. Because of the clinical success of SVR for STI, we
expanded the criteria for SVR to include patients with MTI
and present our initial results with SVR for this patient
population.
Methods
Study Design
The cases of 51 consecutive patients with SVR between January
2002 and June 2004 were retrospectively reviewed after institu-
tional review board approval. The inclusion criterion for patients
with MTI was the clear presence of infarction in two or three left
ventricular vascular territories. Three regions of the left ventricle
were identified by vascular supply: anteroapicoseptal (left anterior
descending coronary artery), lateral (circumflex coronary artery),
and inferior (right coronary artery). The presence of infarction in
these territories was determined by direct observation of full-
thickness scar in the opened left ventricle during surgery and was
correlated with preoperative magnetic resonance imaging (MRI),
cardiac catheterization, and echocardiography. MRI was the pri-
mary imaging modality used for preoperative and postoperative
evaluation of left ventricular hemodynamics, wall thinning, scar-
ring, wall motion abnormalities, shape, and volumes. Cardiac
catheterization was used to determine acceptable targets for revas-
cularization. Exclusion criteria were any of the following: absence
of nonviable anterior wall myocardium, no akinetic or dyskinetic
segments, minor evidence of left ventricular dilatation, poor basi-
lar function, and unreconstructable coronary or mitral disease. The
presence of MTI was not considered an exclusion criterion in this
study. Thirty-three patients with MTI were included in this study,
and 18 patients undergoing SVR for STI formed a comparison
group.
Patient Variables
Data collection included demographic characteristics, preoperative
and postoperative New York Heart Association (NYHA) func-
tional status, hemodynamic and operative data, postoperative com-
plications, and follow-up interviews. Mortality data were retrieved
from autopsy reports, death certificates, the Social Security Death
Index, and physician records. Follow-up was 100% complete, with
a mean follow-up of 16.9  9.4 months. Quality of life assess-
ments were available for 23 patients with MTI who were evaluated
by telephone with the Short Form 12 quality assessment tool.
Statistical Analysis
Data were collected for statistical analysis with SPSS version 11.5
statistical software (SPSS Inc, Chicago, Ill). The primary end point
was overall mortality. Secondary end points included postopera-
tive complications, the need for additional cardiac surgery, length
of stay, and worsening or persistent NYHA class III or IV status.
The Fisher exact test and Student t test were used to conduct
qualitative and quantitative variable analyses, respectively. Cox
regression analysis was performed to determine predictors of mor-
tality. Descriptive statistics are presented as mean  SD unless
otherwise stated. Actuarial survival was calculated with the
Kaplan-Meier method and compared by log rank analysis with that
of patients who underwent SVR for STI.
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Our operative technique has been previously described.8 The de-
cision to perform SVR on the beating or arrested heart was made
at the time of surgery on the basis of clamp time, concomitant
procedures, and cardiac function. Our group prefers to perform
SVR on the arrested heart whenever possible. In brief, after cor-
onary artery bypass grafting and mitral valve repair or replace-
ment, a ventriculotomy is made through the anterior myocardial
wall parallel to the left anterior descending coronary artery. This
incision extends distally to the apex and proximally as needed. The
left ventricular walls are inspected for the presence of MI. An
intraventricular sizing device (Chase Medical, Richardson, Tex;
Bioventrix, Danville, Calif) is deployed into the left ventricle and
is seated on the mitral annulus to aid in the reshaping process. The
size of the intraventricular sizing device is based on patient body
surface area in an effort to approach an optimal LVEDVI of 50 to
60 mL/m2. The apex of the sizing device defines the new apex of
the left ventricular chamber. A purse-string suture begins at the
newly defined apex and runs along the septum, transitioning to the
anterior wall. The suture is then carried down the anterior wall
toward the apex along the anterior aspect of the intraventricular
sizing device, outlining the new anterior wall. The tightness of the
purse-string suture is determined by intraoperative surgical judg-
ment with the intent of reducing the anterior ventriculotomy to
prevent a spherical chamber. Tying the purse-string suture too
tightly can result in a spherical ventricle that is excessively small.
After the purse-string suture is tied, the residual defect in the
anterior wall is closed with an oval Dacron polyester fabric patch
if larger than 2 to 3 cm; otherwise, a linear closure is performed.
Septal scarring and thinning is assessed at the time of surgery and
with preoperative MRI studies. Our method of anteroseptal recon-
struction excludes no more than half of the height of the septum,
whether a patch is used or a primary closure is performed.
Most patients with MTI underwent intraventricular balloon
guided anterior wall reconstruction. The decision to plicate the
lateral or inferior wall is made at the time of surgery according to
Figure 1. A, Surgical plication of inferiorthe surgeon’s subjective assessment of the amount of scarring and
1700 The Journal of Thoracic and Cardiovascular Surgery ● Decdilatation in these territories. In patients with inferior or lateral
infarcts, the scar is addressed with a linear plication. Inferior wall
infarction with an interpapillary muscle distance greater than 3 cm
is plicated with a suture running between the papillary muscles and
ending at the apex (Figure 1, A). For patients with lateral wall
infarcts, the plication suture begins at the base of the infarction and
is carried to the apex (Figure 1, B). The anterior defect is then
closed as previously described.
Results
Clinical Characteristics
Preoperative and intraoperative assessment of patients un-
dergoing SVR demonstrated that 64.7% (33/51) had MTI.
Of these patients, 60.6% (20/33) had a three-territory infarct,
and 39.4% (13/33) had a two-territory infarct (Figure 2). The
clinical characteristics of patients with MTI are presented in
ct. B, Surgical plication of lateral infarct.infarFigure 2. Distribution of patients according to evidence of MI.
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tients with STI. Mean age was 61.6  11.1 years (range
40-81) with a male/female ratio of 29:4. All patients with
MTI had a diagnosis of CHF, 78.8% (26/33) had three-
vessel coronary artery disease, and 78.8% (26/33) had a
presentation of angina. Before the operation, 97.0% of
patients with MTI (32/33) were in NYHA functional
class III or IV. The remaining patient was in functional
class II.
Operative Data
Operative data are also presented in Table 1 and are similar
for patients with STI and those with MTI. Four patients with
TABLE 1. Clinical characteristics and operative data
Clinical characteristics
Male
White
Age (y, mean  SD and range)
Renal failure
Atrial fibrillation
Previous stent or percutaneous transluminal angioplasty
Angina
Syncope
Three-vessel CAD
Smoking
Obesity
Hypertension
Diabetes
COPD
Hyperlipidemia
Preoperative NYHA functional class
I
II
III
IV
Operative data
Mitral valve replacement
Mitral valve repair
Intraventricular balloon
Patch reconstruction
No. of grafts in revascularization
5
4
3
2
1
CPB time (min, mean  SD)
Crossclamp time (min, mean  SD)
IABP
All data are numbers of patients and percentages unless otherwise indic
infarction; CAD, coronary artery disease; COPD, chronic obstructive pulmon
IABP, intra-aortic balloon pump.MTI underwent mitral valve repair, and 1 required mitral
The Journal of Thoracicvalve replacement. Nine patients (27.3%) required intraop-
erative intra-aortic balloon pump (IABP) counterpulsation
according to the assessment of myocardial function at the
time of SVR. An intraventricular sizing device was used in
87.9% of patients (29/33), and a Dacron polyester fabric
patch was used for anterior wall reconstruction in 42.4% of
patients (14/33). Concomitant revascularization with an in-
ternal thoracic artery or saphenous vein was performed in
93.9% of patients (31/33). One patient who did not undergo
concomitant coronary artery bypass grafting had previously
undergone a stenting procedure and was therefore consid-
ered to have complete revascularization. The second patient
had incomplete revascularization because of poor target
MTI (n  33) STI (n  18) P value
29 (87.9%) 14 (77.8%) .43
27 (81.8%) 15 (83.3%) .999
61.6 11.1 (40-81) 64.5 6.7 (48-75) .32
4 (12.1%) 2 (11.1%) .999
6 (18.2%) 5 (27.8%) .49
10 (30.3%) 7 (38.9%) .55
26 (78.8%) 12 (66.7%) .52
3 (9.1%) 5 (27.8%) .08
26 (78.8%) 13 (72.2%) .999
26 (78.8%) 12 (66.7%) .5
7 (21.2%) 2 (11.1%) .46
23 (69.7%) 13 (72.2%) .999
17 (51.5%) 6 (33.3%) .25
4 (12.1%) 4 (22.2%) .43
26 (78.8%) 15 (83.3%) .999
0 (0%) 0 (0%) .999
1 (3.0%) 1 (5.6%) .999
14 (42.4%) 10 (55.6%) .4
18 (54.5%) 7 (38.9%) .38
1 (3.0%) 1 (5.6%) .999
4 (12.1%) 4 (22.2%) .43
29 (87.9%) 16 (88.9%) .999
14 (42.4%) 12 (66.7%) .14
2 (6.1%) 1 (5.6%) .999
4 (12.1%) 1 (5.6%) .64
15 (45.5%) 5 (27.8%) .25
7 (21.2%) 5 (27.8%) .73
3 (9.1%) 0 (0%) .54
50.4 61.0 125.5 66.8 .18
85.0 26.8 76.2 28.1 .28
9 (27.3%) 2 (11.1%) .29
MTI, Multiterritory myocardial infarction; STI, single-territory myocardial
isease; NYHA, New York Heart Association; CPB, cardiopulmonary bypass;1
ated.
ary dvessels. This patient was in preoperative NYHA functional
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tisystem organ failure.
EF and Left Ventricular Volumes
In the MTI group, SVR significantly improved left ven-
tricular EF and volumes on MRI (Table 2). Mean EF
improved from a preoperative value of 25.9%  10.7% to
36.2%  7.7% at follow-up (P  .01). Mean left ventric-
ular end-systolic volume index (LVESVI) improved from a
preoperative value of 117.9  72.7 mL/m2 to 68.8  24.4
mL/m2 at follow-up (P .01). Mean LVEDVI was reduced
from a preoperative value of 146.4  83.2 mL/m2 to
105.1  34.1 mL/m2 at follow-up (P  .04). Postoperative
echocardiography also demonstrated significant improve-
ment in EF (Table 2).
When comparing patients with STI versus those with
MTI, the mean preoperative EF values (29.4%  16.7% vs
25.9% 10.7, P  .49) and postoperative EF values
(39.7%  14.6% vs 36.2%  7.7%, P  .4) were similar
between the two groups according to MRI. Echocardiogra-
phy confirmed these results, with patients with STI demon-
strating a mean postoperative EF of 32.9%  15.7% and
those with MTI having a postoperative EF of 32.6% 
11.7% (P  .9). Mean preoperative EF by echocardiogra-
phy also showed no difference between STI and MTI
groups (20.7%  7.3% vs 25.8%  10.7, P  .12). Fur-
thermore, no difference was seen between the two groups for
mean postoperative LVESVI (69.3  39.9 mL/m2 vs 68.8 
24.4 mL/m2, P  .999) or LVEDVI (108.1  39.3 mL/m2 vs
105.1  34.1 mL/m2, P  .8).
Mitral Valve Regurgitation
Four patients with MTI underwent mitral valve repair (ring
annuloplasty), and 1 required mitral valve replacement at
the time of SVR. Three patients with mitral valve repair had
improvement in function with no mitral regurgitation (MR)
to mild MR at follow-up. The fourth patient had no post-
operative change in MR and later required left ventricular
TABLE 2. MRI and echocardiographic data for patients
with MTI
Preoperative Postoperative P value
MRI n 25 n  19
EF (%) 25.9% 10.7% 36.2% 7.7% .01
LVESVI (mL/m2) 117.9 72.7 68.8 24.4 .01
LVEDVI (mL/m2) 146.4 83.2 105.1 34.1 .04
Echocardiography n 24 n  30
EF (%) 25.8 10.7 32.6 11.7 .03
All data are mean  SD. MRI, Magnetic resonance imaging; MTI, multi-
territory myocardial infarction; EF, ejection fraction; LVESVI, left ventricular
end-systolic volume index; LVEDVI, left ventricular end-diastolic volume
index.assist device (LVAD) implantation. Two patients had mod-
1702 The Journal of Thoracic and Cardiovascular Surgery ● Decerate to severe MR according to preoperative echocardio-
graphy, but a mitral valve procedure was not performed in
these 2 cases because both patients demonstrated no MR to
mild MR on intraoperative transesophageal echocardiogra-
phy before SVR.
Postoperative Complications and Procedures
Postoperative complications are noted in Table 3. Compli-
cation rates were similar between the two groups, although
the patients with MTI required more frequent transfusions
in the postoperative period (P  .04). Twenty-one percent
(7/33) required additional surgery, including 2 sternal
wound débridements, 3 LVAD implantations, and 2 auto-
matic implantable cardioverter defibrillator implantations in
those patients with inducible ventricular arrhythmias demon-
strated in the electrophysiology laboratory. After the operation,
9.1% (3/33) required IABP counterpulsation. Postoperative
IABP support was indicated by hemodynamic instability and
increasing intravenous inotropic agent requirements.
Mortality
Two (6.1%) operative deaths from multisystem organ fail-
ure occurred on PODs 15 and 25. This did not differ
statistically from the operative mortality for patients under-
going SVR for STI at our institution (11.1%; P  .61). Late
TABLE 3. Postoperative procedures and complications
MTI
(n  33)
STI
(n  18)
P valueNo. % No. %
IABP 3 9.1% 2 11.1% .999
Atrial fibrillation 8 24.2% 4 22.2 .999
Ventricular tachycardia 3 9.1% 1 5.6% .999
Junctional rhythm 1 3.0% 0 0% .999
Pacemaker 2 6.1% 0 0% .53
Bleeding necessitating
reoperation 1 3.0% 0 0% .999
Transfusion 7 21.2% 0 0% .04
Deep vein thrombosis 5 15.2% 2 11.1% .999
Stroke 3 9.1% 1 5.6% .999
Infection
Sternal infection 2 6.6% 1 5.6% .999
Pneumonia 5 15.2% 1 5.6% .41
Urinary tract infection 4 12.1% 1 5.6% .64
Sepsis 3 9.1% 1 5.6% .999
Additional surgery
Débridement 2 6.6% 1 5.6% .999
LVAD placement 3 9.1% 1 5.6% .999
Defibrillator implantation 2 6.1% 2 11.1% .61
MTI, Multiterritory myocardial infarction. STI, single-territory myocardial
infarction; IABP, intra-aortic balloon pump; LVAD, left ventricular assist
device.mortality in the MTI group was 19.4% (6/31), which did not
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.40). The causes of late mortality in the MTI group were
gastrointestinal bleeding after LVAD placement (n  1),
CHF (n  1), sepsis (n  1), multisystem organ failure
(n  1), LVAD-related complication (n  1), and unknown
causes (n  1).
Actuarial survivals (including in-hospital deaths) at 6,
12, 18, 24, and 30 months were 84.3%, 78.4%, 78.4%,
73.5%, and 73.5%, respectively, which did not differ statis-
tically from those of patients with STI (Figure 3). When
patients with MTI who had LVESVI greater than 100
mL/m2 were compared with those who had LVESVI less
than 100 mL/m2, the latter group demonstrated a statist-
ically significant improvement in actuarial survival at 2
years (84.8%  8.4% vs 44.4%  16.6%, P  .007).
Similarly, patients with LVEDVI less than 130 mL/m2
demonstrated a significant improvement in actuarial sur-
vival at 2 years relative to those with LVEDVI greater than
130 mL/m2 (83.1%  9.3% vs 55.6%  15.0%, P  .04).
Cox Regression Multivariable Analysis
Cox regression analysis was performed to determine inde-
pendent predictors of mortality in the MTI group. Variables
used in the analysis included age older than 60 years, chronic
obstructive pulmonary disease, incomplete revascularization,
recent MI (30 days), diabetes, three-territory MI, NYHA
functional class IV, LVESVI greater than 100 mL/m2, preop-
erative renal failure requiring dialysis, pulmonary hyperten-
sion, preoperative atrial fibrillation, and previous stenting.
Of these variables, LVESVI greater than 100 mL/m2 re-
sulted in a 12-fold increase in mortality (P  .03, 95%
confidence interval 1.27-114.51).
Functional Outcomes
SVR significantly improved functional outcomes for pa-
Figure 3. Distribution of patients with STI (anterior) versus MTI.tients with MTI (Figure 4). Before the operation, 97.0% of
The Journal of Thoracicpatients (32/33) were considered to be in NYHA functional
class III or IV; this had improved to 30.3% (10/33) at
follow-up (P  .01). Sixty-nine percent of patients (22/32)
with MTI in preoperative NYHA functional class III or IV
had improvement to class I or II at follow-up (P  .01).
Short Form 12 telephone questionnaire data, available
for 23 patients with MTI, indicated that 69.6% (16/23)
reported their general health as good to excellent after SVR.
Furthermore, 78.3% (18/23) of patients with MTI indicated
little to no limitation in physical activities after the procedure.
Discussion
SVR is an established treatment for ischemic cardiomyop-
athy resulting from STI. Revascularization performed con-
comitantly with SVR improves left ventricular size, EF, and
NYHA functional class in patients with anterior akinetic or
dyskinetic scar5-7,9-11 and improves regional myocardial
performance in remote nonischemic areas.12,13
Despite this success, patients with CHF resulting from
MTI have been denied SVR because these patients were
believed to face a greater operative risk. Previous studies by
Menicanti and colleagues4 and Mickleborough and col-
leagues5 have described operative techniques for managing
large apical aneurysms by plicating the posterior wall. Some
of these patients may have had MTI, but the populations
were not clearly defined, and outcomes in patients with MTI
have not been specifically addressed. In a recent study,
Mickleborough and colleagues5 stated that SVR was not
contraindicated for patients with gross chamber dilatation
and extensive wall motion abnormalities. We believe that
postinfarction enlargement does not reflect the territory of
MI. Many patients in our study had markedly dilated left
ventricles with extensive wall motion abnormalities and still
Figure 4. Preoperative (light bars) versus postoperative (dark
bars) NYHA functional class for patients with MTI undergoing
SVR. Asterisk indicates P < .05.demonstrated STI on intraoperative assessment and preop-
and Cardiovascular Surgery ● Volume 130, Number 6 1703
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Donato and associates6 described 14 patients undergoing
SVR with anterior wall MI and remote asynergy. That
study, however, provided no conclusive evidence (intraop-
erative observation of full-thickness scarring or MRI data)
to demonstrate MTI in those 14 patients. We specifically
evaluated outcomes after SVR in patients with confirmed
MTI. We saw significant improvements in EF, left ventric-
ular volumes, and NYHA functional status, with acceptable
survival for these high-risk patients.
Some centers use the transition zone between contractile
and noncontractile myocardium, among other factors, to
determine the margins of anterior wall reconstruction5; oth-
ers use the base of the papillary muscles as a guide.9 In
patients with diffuse disease and MTI, this transition zone
can be difficult to recognize. In this setting, and for patients
with large ventricles, we have found commercially available
intraventricular sizing devices to be extremely helpful. For
patients who have enlargement in two or more territories,
these sizers can act as templates for plication of the inferior
and lateral walls. This allows the restoration of normal
chamber geometry while excluding as much fibrous scar as
possible.
We saw significant improvement on MRI in EF,
LVESVI, and LVEDVI. These results are similar to those
previously reported by centers evaluating outcomes after
SVR for STI.5-7,9-11 We recognize that MRI is not as readily
available as echocardiography when assessing cardiac func-
tion. Echocardiography is therefore commonly used to mea-
sure left ventricular dimensions, EF, and mitral valve func-
tion when MRI is unavailable. However, echocardiography
clearly cannot provide the sensitivity and specificity that
MRI allows. We recommend MRI when available for as-
sessing cardiac function for patients undergoing SVR. MRI
is especially important for assessing left ventricular function
in patients with MTI, because the lateral and inferior walls
can be visualized to assess dilatation and thinning.
We performed a subset analysis of outcomes for two-
versus three-territory MI but did not find any differences in
survival or cardiac function. However, these inconclusive
findings may result from a type II error. Our early experi-
ence with patients undergoing SVR for MTI leads us to
believe that lateral wall MI may be a predictor of worse
outcome, because we believe that the lateral wall contrib-
utes more to the function of the left ventricle than does the
inferior wall. We hope to further analyze the impact of two-
versus three-territory MI and the presence of lateral versus
inferior MI in future studies.
Recent reports have demonstrated that left ventricular
volumes are a significant predictor of outcome. White and
associates,14 Yamaguchi and colleagues,15 and the recent
Global Utilization of Streptokinase and t-PA for Occluded
Coronary Arteries trial16 each demonstrated poorer survival
1704 The Journal of Thoracic and Cardiovascular Surgery ● Decfor patients with LVESVI greater than 60 mL/m2. Our study
demonstrated 42% and 28% decreases in LVESVI and
LVEDVI, respectively, after SVR. Additionally, our pa-
tients with MTI who had LVESVI greater than 100 mL/m2
faced a significant increase in mortality relative to those
who had LVESVI less than 100 mL/m2. Our LVESVI cutoff
for increased risk of death was higher than previously
reported,14-16 but this can be explained by a significantly
higher average LVESVI in our patient population than in
those in previous studies.5-7 In addition, increasing the
number of patients in our cohort would likely have reduced
this LVESVI threshold.
MR is common among patients with ventricular enlarge-
ment because annular dilatation and chordal restriction in-
hibit effective leaflet coaptation.17 In our series, 4 patients
with MTI underwent mitral valve repair concomitantly with
SVR, and 1 patient required mitral valve replacement. Im-
proved left ventricular geometry after SVR can reduce the
degree of MR; however, surgery may also worsen papillary
muscle or chordal restriction in some cases. Intraventricular
sizing devices may help to avoid this complication, as can
be seen in our series, in which none of our patients dem-
onstrated worsening of mitral valve function. Our current
recommendations include the use of intraventricular sizing
devices where appropriate and a concomitant mitral valve
procedure in any patient with worse than mild MR.
In our cohort, 3 patients with MTI required LVAD
placement at 3, 9, and 35 days. All 3 of these patients had
three-vessel coronary artery disease and a preoperative EF
no greater than 20%, with a history of MI 4 days, 2 weeks,
and 1 year before SVR. Two patients died in the hospital,
one on POD 60 of complications from rectal cancer and the
other on POD 129 of LVAD-related complications. The
final patient who required LVAD implantation died at 18
months from massive gastrointestinal bleeding. From our
experience, we believe that the anatomic consequences of
SVR do not preclude patients from future LVAD implan-
tations if necessary. We therefore discuss LVAD implanta-
tion with patients who fulfill the accepted criteria in the
event that SVR fails to improve cardiac function.
Our 30-month actuarial survival of 73.5%  8.3% for
patients undergoing SVR for MTI is not statistically differ-
ent from our survival of patients undergoing SVR for STI
(82.5% 9.2%). Other studies have demonstrated excellent
survival after SVR. Mickleborough and colleagues5 re-
ported a 30-month survival of approximately 85% for 174
patients with CHF undergoing SVR, which was signifi-
cantly worse than the survival for patients without CHF in
the same study (n  111). They also found that CHF and
preoperative EF lower than 20% were predictors of poor
5-year outcome on multivariable analysis. The recent RE-
STORE multicenter study7 reported 30-month survivals of
approximately 85% for patients in preoperative NYHA
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IV. In the same RESTORE study, patients with mean pre-
operative EF lower than 30% and LVESVI greater than
80 mL/m2 had 30-month survivals of approximately 80%
and 75%, respectively. Our initial experience with SVR for
patients with CHF and MTI, who had mean preoperative EF
of 26% and LVESVI of 118 mL/m2, demonstrates encour-
aging early and midterm clinical results despite severe left
ventricular dysfunction and markedly dilated left ventricular
volumes before the operation.
Although we have demonstrated that patients with CHF
and full-thickness MI in multiple left ventricular vascular
territories are candidates for SVR, there clearly must be
some amount of viable myocardium remaining. However,
this amount has yet to be determined. Our belief is that the
base of the heart is most critical, and so we offer SVR to
candidates with MTI who retain basilar function. We are
able to visually assess basilar function with MRI, but the
current technology does not permit us to quantify these
findings. We hope that future advances in MRI technology
will allow us to determine the function and viability of
individual left ventricular segments quantitatively and thus
enable the cardiac surgeon to identify appropriate candi-
dates for SVR.
Our study is limited by retrospective analysis, a small
patient cohort, and a relatively short follow-up interval.
Even with these limitations, however, we were able to
demonstrate similar survivals, improvements in cardiac
function, and improvements in quality of life for patients
with MTI and STI. Longer follow-up and a larger patient
cohort will enable us to make better long-term conclusions
about SVR for patients with MTI, but our initial results are
quite promising.
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Discussion
Dr Lorenzo A. Menicanti (San Donato, Italy). SVR is a well-
established procedure that represents a useful surgical tool. It was
proposed at the beginning for classic aneurysmal dilatation of the
left ventricle after acute anteroseptal MI. With increased experi-
ence, the procedure has been applied to a larger spectrum of
pathology, particularly to real postischemic cardiomyopathy, and
this study is a clear demonstration. It is evident, as pointed out here
by Patel and colleagues, that to be successful a critical amount of
working myocardium necessary to sustain the systemic circulation
must be present at the end of the procedure. So it is not only a
problem of the number of territories involved but mainly of ex-
tension of the infarction and consequently of quality and quantity
of remaining tissue. This article described 33 patients with dilated
postischemic cardiomyopathy determined by MTI. These patients
represent a very difficult cohort with increased surgical risk.
I have three questions for you, Dr Conte. First, according to
your experience and your MRI analysis, what contraindication
criteria have you adopted in your clinical practice?
Second, we know that even after a successful procedure with
good reduction of left ventricular volume, a few patients are seen
4 to 6 months later with an increase in left ventricular dimension.
Do you have the same results, and if so, do you have some
predictive criteria for this evolution?
Third, mitral insufficiency plays an important role in this group
of patients, and when it is addressed, the mortality is increased. In
your article, you describe a few cases in which mitral insufficiency
disappeared after SVR alone. Can you comment on this and define
your strategy for this challenging subgroup of patients?
Dr Conte. Dr Menicanti, thank you for those insightful com-
ments. I acknowledge your contribution to this field; without you
and Cardiovascular Surgery ● Volume 130, Number 6 1705
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at all.
First, all procedures have contraindications, and I think this is
a difficult group in which to identify absolutes, but certainly there
is some quantifiable amount of muscle that must remain for us to
be able to successfully perform this operation. I don’t think we
have identified that yet, but I am optimistic that with MRI tech-
niques and like technologies we will be able to quantify the exact
amount of muscle necessary to support the circulation, or at least
to determine the amount that will lead to operative failure. So I
think the only patients I would not consider are those patients who
have little to no basilar function retained, because in my experi-
ence those are absolutely the patients who do not do well, and you
have to have at least one or preferably two basilar segments
remaining to have a successful outcome.
Second, you asked how long to wait after an infarction to
perform this operation. The video we showed nicely demonstrated
very thick scar tissue, and that makes the operation somewhat
easier and certainly a pleasure to perform, but it is not always
there. So I would recommend waiting at a minimum 3 months,
preferably 6 months if you can. This operation is best performed
for chronic rather than acute heart failure. Some of the patients in
our series came to light because of acute infarction, but as we
evaluated these patients preoperatively, they clearly had evidence
of old infarctions, and that was the indication for remodeling in
these patients with acute infarctions. So certainly I would wait 6
months, if possible.
The final question had to do with MR, and I have actually
significantly changed my approach to these patients. My goal is to
leave the operating room with no MR in these patients, if possible.
A few patients who have not had mitral repairs performed have
still had a reduction in the amount of MR. It seems to me that the
reason for that is that, just like in the diagram I showed for the
inferior plication, the papillary muscles are brought closer together
and probably toward the mitral annulus a little bit. That may
reduce some of the restriction on those papillary muscles and
chords, decreasing the tethering and allowing those leaflets to
coapt a little bit better. I think that is the mechanism for the
successful reduction in MR.
Conversely, when we do this operation we run the risk, partic-
ularly when we put our purse-string too close to the papillary
muscles, of restricting the papillary muscles and chords even more,
1706 The Journal of Thoracic and Cardiovascular Surgery ● Decworsening the MR. So it is certainly a sensitive situation some-
times.
Dr Robert Guyton (Atlanta, Ga). I congratulate you on the
series. The question I have is regarding the use of the IABP. I find
these patients to be ideal candidates for prophylactic use of an
IABP. As you are aware, a couple of prospective series have
shown that for these high-risk patients, prophylactic use of the
IABP decreases intensive care unit and hospital stays. Particularly
because we can now put the IABPs in with a relatively low risk if
we use transesophageal echocardiographic guidance and survey of
the descending aorta, would this group of patients not be an ideal
group for prophylactic use of an IABP?
Dr Conte. Absolutely; I couldn’t agree more. Ever since we
began doing this operation several years ago, that is the exact
approach we have taken. Every patient has an arterial line placed
in the groin in preparation for an IABP. If I went back and actually
really looked at those patients who received an IABP, approxi-
mately a third of the total, I would tell you that those are the
patients with extremely poor function, with larger ventricles. We
have an extremely low threshold for putting in the IABPs, and we
keep them in until we are able to begin vasodilators in the intensive
care unit. Many of these patients require postoperative vasodilators
and in fact will even be transferred to the step-down unit or the
floor with a regimen of milrinone or like agents.
Dr Radu Deac (Targu-Mures, Romania). I congratulate you
for the excellent results you obtained with a difficult group of
patients. We have a much smaller series of patients, all of whom
survived the operation. The long-term results of this group were
not as good for all of them. I have one question. What is the rule
to design the size of the patch, since the patch remains an akinetic
area in the anterior ventricular wall?
Dr Conte. That is a good question, but I don’t think there is any
good answer. The practice that I have taken up is really just to go
and look at it, and if it is larger than about 3 cm, I patch everybody.
One of the risks I think you do run is if you have a long anterior
ventriculotomy and you put a large purse-string in there and then
you do not patch it, as you close that anterior ventriculotomy you
are going to pull on the papillary muscles, restrict leaflet motion a
little bit, and worsen the MR. So I think it is particularly important
in patients with very large ventricles or those who have had
extremely proximal anterior infarctions to place a patch.
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